Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to ...
Maze Therapeutics (MAZE) announced the first patient has been dosed in the company’s Phase 2 clinical trial, the HORIZON Study, of MZE829 in ...
Maze Therapeutics, Inc. (NASDAQ: MAZE), a clinical-stage biopharmaceutical company with a market capitalization of $569 million, has dosed the first patient in its Phase 2 HORIZON Study of MZE829, ...
Within the open-label basket trial, patients with two copies of one of two high-risk APOL1 gene variants will receive MZE829.
A year after guidelines were revised to remove the use of race in eGFR, many labs and pathologists were still relying on the ...
An oft-repeated message is that primary aldosteronism is not rare; it is quite common. An equally urgent message is that ...
New GLP-1RA weight loss drugs like Like Ozempic and Wegovy have become extremely popular in recent months but researchers ...
In patients with frequent severe hypoglycaemic events, allogeneic pancreatic islet transplantation results in better glycaemic control than insulin therapy alone, enhances quality of life, and reduces ...
The New England Journal of Medicine has published a detailed analysis of Genentech’s positive results from the Phase III REGENCY study of Gazyva® (Obinutuzumab) for people with active lupus nephritis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback